Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer

International Journal of Clinical Oncology

Volumn 17, Issue 4, 2012, Pages 341-347

  Inoue, Naohiko ^a   Ishida, Hideyuki ^a   Sano, Motohiko ^a   Kishino, Tohru ^a   Okada, Norimichi ^a   Kumamoto, Kensuke ^a   Ishibashi, Keiichiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; DEB NTC; NCI CTCAE; Oxaliplatin; Peripheral neurotoxicity

Indexed keywords

FLUOROURACIL; IRINOTECAN; LEVOLEUCOVORIN; OXALIPLATIN;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NATIONAL CANCER INSTITUTE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS SCALE; NEUROTOXICITY; NEUROTOXICITY CRITERIA FOR DEBIOPHARM SCALE; PERITONEUM METASTASIS; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; REFERENCE STANDARDS; UNITED STATES;

EID: 84867333922     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0298-z     Document Type: Article

References (30)

1. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combination in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30
2. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
3. André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAC trial. J Clin Oncol 27:3109-3116
4. Stephanie RL, Jacek AK, Reena SC et al (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25:2205-2211
5. Grothey A (2003) Oxaliplatin-safety profile: Neurotoxicity. Semin Oncol 30:5-13
6. Cavaletti G, Tredici G, Petruccioli MG et al (2001) Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 37:2457-2463
7. Krishnan AV, Goldstein D, Friedlander M et al (2005) Oxaliplatin- induced neurotoxicity and the development of neuropathy. Muscle Nerve 32:51-60
8. Grothey A (2005) Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5(Suppl 1):S38-S46
9. Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476-487
10. Gamelin E, Gamelin L, Bossi L et al (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures. Semin Oncol 29(5 Suppl 15):21-33
11. Choi J, Kong K, Mozaffar T et al (2006) Delayed oxaliplatin associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anti-cancer Drugs 17:103-105
12. Imada H, Kwakami K, Hiraoka T et al (2007) Drug information brochure for patients undergoing FOLFOX4 chemotherapy based on survey of adverse reaction. Peripheral neurotoxicity. J Cancer Chemother 34(9):1425-1430
13. Shouji D, Matsusaka S, Watanabe C et al (2008) Relative dose intensity of FOLFOX4 regimen. Jperipheral neurotoxicity. J Cancer Chemother 35(11):1895-1900
14. Gamelin L, Boisdron-Celle M, Delva R et al (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055-4061
15. Cascinu S, Catalano V, Cordella L et al (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo- controlled trial. J Clin Oncol 20(16):3478-3483
16. Wilson RH, Lehky T, Thomas RR et al (2002) Acute oxaliplatininduced peripheral nerve hyperexcitability. J Clin Oncol 20: 1767-1774
17. Tournigand C, Cervantes A, Figer A et al (2006) OPTMOX1: A randomized study of FOFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-A GERCOR study. J Clin Oncol 24:394-400
18. Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237
19. Maindrault-Grobel F, Tournigand C, André T et al (2004) Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil, and oxaliplatin for metastatic colorectal cancer. Ann Oncol 15:1210-1214
20. National Cancer Institute. National Cancer Institute Common Toxicity Criteria version 3.0. http://ctep.cancer.gov/
21. Boku N, Ohtsu A, Hyodo I et al (2007) Phase II study of oxaliplatin in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. Jpn J Clin Oncol 37:440-445
22. Christian L et al (2002) Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2:54-58
23. Lévi F, Perpoint B, Garufi C et al (1993) Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 29:1280-1284
24. Allegra CJ, Yothers G, O'Connell MJ et al (2011) Phase III trial assessing bevacizumab in sages II and III carcinoma of the colon: Results of NSABP protocol C-08. J Clin Oncol 29:1-4
25. Ishibashi K et al (2010) Effect of calcium and magnesium on neurotoxicity and blood platinum concentration in patients receiving mFOLFOX6 therapy: A prospective randomized study. Int J Clin Oncol 15:82-87
26. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
27. Landis LR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159-174
28. Caussanel JP, Lévi F, Brienza S et al (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. J Natl Cancer Inst 82:1046-1050
29. Nikcevich DA, Grothey A, Sloan JA et al (2008) Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatininduced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG trial N04C7. Proc Am Soc Clin Oncol 26 (abstr 4009)
30. Stephens RJ, Hopwood P, Girling DJ et al (1997) Randomized trials with quality of life endpoints: Are doctors' ratings of patients' physical symptoms interchangeable with patients' selfratings? Qual Life Res 6:225-236